Ralph Tufano, M.B.A., M.D.

• Professor of Otolaryngology - Head and Neck Surgery

https://www.hopkinsmedicine.org/profiles/results/directory/profile/0015647/ralph-tufano

Severe side effects have been described asthmatic bronchitis pneumonia buy fluticasone 100 mcg on line, such as angina asthma definition theory order 250 mcg fluticasone with amex, cardiac arrhythmias asthma treatment malayalam fluticasone 100 mcg purchase amex, intestinal ischemia asthma 7 year cycle buy discount fluticasone 250 mcg line, and severe hypertension asthma symptoms side effects fluticasone 100 mcg without prescription, and patients with ischemic heart disease and peripheral vascular disease should not be treated with terlipressin. The starting dosage of octreotide is 100 mcg three times daily and can be increased to a maximum of 200 mcg three times daily with the same indications of midodrine. Therefore further studies are needed to determine the reliability of this treatment. Effective hypovolemia is caused by a splanchnic arterial vasodilation and a reduction in cardiac output. The compensatory activation of endogenous vasoconstrictors systems such as sympathetic nervous system, the renin-angiotensin-aldosterone system, and nonosmotic secretion of vasopressin leads to severe prerenal arterial vasoconstriction. Translocation of bacteria and/or bacterial product from intestinal lumen to systemic circulation causes a systemic inflammatory response, further increasing the splanchnic arterial vasodilation and impairing the cardiac output. The potential benefit of transjugular intrahepatic portosystemic shunt and extracorporeal systems as a bridge to liver transplantation is still to be determined. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Transplantation of cadaveric kidneys from patients with hepato-renal syndrome: evidence for the functional nature of renal failure in advanced liver disease. Incidence, predictive factors and prognosis of the hepato-renal syndrome in cirrhosis with ascites. Urinaryneutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. Peripheral arteriolar vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Thespectrumofrenal lesions in patients with cirrhosis: a clinicopathological study. A unified theory of sepsisinduced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics and the tubular cell adaptation to injury. Albuminforbacterialinfections other than spontaneous bacterial peritonitis in cirrhosis. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. Primaryprophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Positivecardiacinotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Terlipressintherapywithand without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: effects on kidney function and transplantation outcomes. Systematicreview of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. A metaanalysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. However, CystC levels may be increased in high cell turnover states (such as hyperthyroidism, steroid use, and malignancy), advanced age, gender and ethnicity, fat mass, and diabetes, among others. Suggested therapeutic approaches to prevent, halt, or ameliorate renal dysfunction are also discussed. In a prospective study consisting of 104 patients treated with intravenous amikacin for at least 36 hours, low serum albumin was found to be associated with amikacin accumulation in the plasma and an increased risk of nephrotoxicity. The spectrum of cholemic nephrosis ranges from proximal tubulopathy to bile cast nephropathy. In a clinicopathologic study of 44 jaundiced subjects (41 autopsies and 3 kidney biopsies), 18 had bile casts involving distal nephron segments and 6 had extension to proximal tubules. A significant correlation was found between these casts and higher serum total and direct bilirubin levels (p =. Furthermore, a trend toward higher serum creatinine, aspartate transaminase, and alanine transaminase levels were observed among patients with bile casts compared with those without. In early studies, it demonstrated utility when used as a bridge to maintain renal function until liver transplantation. Terlipressin alone or terlipressin in combination with low-dose albumin was associated with improvement in systemic, renal, and splanchnic hemodynamics. Terlipressin and albumin + terlipressin were associated with decreased cardiac output and portal flow, and increased systemic vascular resistance compared with albumin after 3 and 10 days. In contrast, no significant changes in heart rate, mean arterial pressure, cardiac output, or portal blood flow were observed in the midodrine group compared with the albumin group after 3 or 10 days. Furthermore, plasma renin activity, renal, and hepatic arteries resistive index were significantly higher in the midodrine group compared with the albumin group after 10 days. Nevertheless, renal function on postoperative day 7 and the need for hemodialysis/hemofiltration during the first week were similar in both groups. It is speculated that this is partly due to the reduction in retroperitoneal blood loss, because the piggyback technique does not require retrocaval dissection. In addition, it permits venous return to the heart during the anhepatic phase and avoids hemodynamic variation during inferior vena cava clamping. These may include an anesthesia-induced decrease in effective blood volume, preexisting cardiovascular disease or severe cardiomyopathy, prolonged episode of hemodynamic instability or hypotension, severe intravascular volume depletion, use of drugs that can adversely affect intrarenal hemodynamics, older age, preexisting renal dysfunction, and diabetes mellitus. The 2013 Cochrane review showed a lack of a renoprotective effect of various pharmacologic agents and surgical techniques. It was concluded that there is no reliable evidence from the available literature to suggest that interventions during surgery can protect the kidneys from damage. Nonetheless, control of bleeding during surgery, careful attention to management of fluid and electrolytes, and avoidance of hypotensive episodes may protect the kidneys from hemodynamically mediated ischemic injury. The use of cyclosporine or tacrolimus in the posttransplantation period may exacerbate further renal dysfunction. Biopsy-proven acute rejection rates, and patient and graft survival rates were comparable between the two groups. Five-year patient survival and adverse effects were comparable between the two treatment groups. The study was stopped after 195 patients had been enrolled because of slow recruitment rates and significant between-group differences in acute rejection rates. Manipulation of immunosuppressive therapy to avoid nephrotoxicity should be tailored to each individual patient. At 6-month follow-up, a higher proportion of patients in the belatacept-treated group met the composite end point of acute rejection, graft loss, and death compared with the Tac-treated group (42%­48% vs. However, follow-up beyond 12 months revealed an increase in mortality rate and graft loss in high-dose belatacept-treated groups, necessitating early termination of the study. Rates of adverse events, serious adverse events, and discontinuation because adverse events were similar in both groups. Randomization to Tac elimination was terminated prematurely because of a higher rate of biopsy-proven acute rejection during Tac withdrawal. Biopsy-proven acute rejection, graft loss, death, and adverse events leading to drug discontinuation were comparable between the two treatment groups. The 5-year patient and graft outcomes were comparable between the two treatment groups. In addition to manipulation of immunosuppressive therapy, blood pressure control and aggressive management of comorbid conditions such as diabetes mellitus and dyslipidemia are recommended. Statins have been shown to be safe and effective in treating hypercholesterolemia after liver transplantation. Nonetheless, close monitoring of liver function tests after statin therapy is mandatory. The most common indications for conversion therapy included renal dysfunction (32. The study findings suggest that early conversion therapy is associated with better renal function recovery. In general, albumin has been suggested to be more effective than artificial plasma expanders in the prevention of circulatory dysfunction. Although nonnephrotoxic, belatacept and de novo sirolimus use after liver transplantation are associated with increased mortality and graft loss and their use should be avoided. Various immunosuppressive strategies to improve renal function after liver transplantation are summarized in Table 129. Therefore careful selection of candidates for combined kidney-liver transplantation avoids added renal-related complications after liver transplantation. In large volume paracentesis, albumin infusion at a dose of 1 g per kg body weight up to 100 g/day is recommended. Intraoperative risk factors for the development of perioperative acute kidney injury are likely similar to those in nontransplant surgical settings. Aggressive control of intraoperative bleeding, management of fluid and electrolyte abnormalities, and avoidance of hypotensive episodes are imperative in the perioperative period. Bleeding and infectious complications should be treated promptly and aggressively. The use of calcineurin inhibitor­sparing protocols in patients with preexisting hepatorenal syndrome or pretransplant renal dysfunction should be individually tailored. Manipulation of immunosuppressive therapy such as calcineurin inhibitor minimization or withdrawal in the face of severe acute kidney injury may be futile. The added risks of acute rejection should be weighed carefully against the benefits. Belatacept and de novo sirolimus use after transplantation should be avoided because of increased mortality risk and graft loss. Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Benefit of cystatin C in evaluation of renal function and prediction of survival in patients with cirrhosis. SerumcystatinCasan indicator of renal function and mortality in liver transplant recipients. Renalfunctionoutcomes following liver transplantation and combined liver-kidney transplantation. An epidemiology study of early renal replacement therapy after orthotopic liver transplantation. Hyponatremia impairs early posttransplant outcome in patients with cirrhosis undergoing liver transplantation. Glomerulonephritis in patients with hepatitis cirrhosis undergoing liver transplantation. Hypoalbuminemia and acute kidney injury: a meta-analysis of observational studies. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation. Terlipressinplusalbuminis more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis. Effect of venous bypass on postoperative renal function in liver transplantation: results of a randomized, controlled trial. Prospective randomized trial comparing hepatic venous outflow and renal function after conventional versus piggyback liver transplantation. The safety of modern hydroxyethyl starch in living donor liver transplantation: a comparison with human albumin. Hydroxyethyl starch and acute kidney injury in orthotopic liver transplantation: a single-center retrospective review. Risk factors for acute kidney injury and 30-day mortality after liver transplantation. The impact of thymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitor in orthotopic liver transplantation. Evaluation of renal function in liver transplant recipients receiving daclizumab (zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant reduction. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain. Improvement of renal function after a switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Mycophenolate mofetil in combination with reduction of calcineurin inhibitor for chronic renal dysfunction after liver transplantation. Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: Clinical results of a prospective randomized study. Calcineurininhibitor sparing with mycophenolate mofetil in liver transplantation: A systematic review of randomized controlled trials. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver transplant patients with renal dysfunction: A randomized controlled study.

Practical considerations in dialysis withdrawal: "To have that option is a blessing asthma symptoms vs heart attack symptoms proven 250 mcg fluticasone. Clinical practice guideline on shared decision making in the appropriate initiation of and withdrawal from dialysis asthma definition yahoo cheap fluticasone online american express. Worldwide similarities and differences in the forgoing of life-sustaining treatments asthma disease definition 100 mcg fluticasone for sale. Increasing incidence of withholding and withdrawal of life support from the critically ill asthma vcd treatment fluticasone 100 mcg purchase mastercard. Withholding and withdrawal of life support in intensive care units in France: a prospective survey asthma symptoms 2 discount fluticasone 100 mcg with amex. Patient preferences for communication with physicians about end-of-life decisions. Relationship of general advance directive instructions to specific life-sustaining treatment preferences in patients with serious illness. A prospective study of the impact of patient preferences on life-sustaining treatment and hospital cost. Determinants in Canadian health care workers of the decision to withdraw life support from the critically ill. End-of-life decision making within intensive care: objective, consistent, defensible Perceived quality of life and preferences for life sustaining treatment in older adults. Variation in the attitudes of dialysis unit medical directors toward decisions 22. Global variability in withholding and withdrawal of life-sustaining treatment in the intensive care unit: a systematic review. Moral justifications for surrogate decision making in the intensive care unit: Implications and limitations. Symptoms of anxiety and depression in family members of intensive care unit patients: ethical hypothesis regarding decision-making capacity. Myth of substituted judgement: surrogate decision-making regarding life-support is unreliable. Patient knowledge and physician predictions of treatment preferences after discussion of advance directives. Shared Decision-Making in the Appropriate Initiation and Withdrawal From Dialysis. A palliative approach to dialysis care: a patient-centered transition to the end of life. Medical research in emergency research in the European Union member states: tensions between theory and practice. Half the family members of intensive care unit patients do not want to share in the decision-making process: a study in 78 French intensive care units. Protecting subjects with decisional impairment in research: the need for a multifaceted approach. Composite outcomes in randomized trials: greater precision but with greater uncertainty Evidence b(i) ased medicine-Selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Clinical Trial Registration: a statement from the International Committee of Medical Journal. The ethical conduct of clinical research involving critically ill patients in the United States and Canada: principles and recommendations. National estimates of intensive care utilization and costs: Canada and the United States. Ethical decision making with end-of-life care: palliative sedation and withholding or withdrawing life sustaining treatments. Recommendations for end-of-life care in the intensive care unit: the Ethics Committee of the Society of Critical Care Medicine. Nurse-physician collaboration and satisfaction with the decision-making process in three critical care units. Recommendations guiding physicians in biomedical research involving human subjects. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (National Commission). Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Is the concept of informed consent applicable to clinical research involving critically ill patients Do surrogate decision makers provide accurate consent for intensive care research Research recruitment practices and critically ill patients a multicenter, cross-sectional study (The Consent Study). Present the specificity to implement intermittent techniques to treat acute renal failure in the intensive care unit. Review the evidence regarding the effect of the type of dialysis membrane and the dialysis dose on the outcome for the patient with acute renal failure. Discuss the basic principles of prescribing intermittent hemodialysis for patients with acute renal failure, including treatments using sustained, low-efficiency intermittent hemodialysis. This method favors small molecule removal, given their high diffusibility across the membrane, and provides a high efficiency (clearance around 200 mL/min). In a standard way, this method is based on a high dialysate flow (500 mL/ min) and needs although a high blood flow (250­300 mL/ min). In addition to diffusion a certain amount of convection called "net ultrafiltration" is used during each session to remove an excess of fluids. In addition, these new methods were thought to improve hemodynamic tolerance and were used widely in most parts of the world. Adaptations must be considered related to blood and dialysate flow, dialysate characteristics, net ultrafiltration, and session duration. Dialysis Machine the machine is devoted to the production of the dialysate using the online prepared pure water and the electrolyte concentrates, to the control of the ultrafiltration, and to the monitoring of the treatment. Recent improvements have been implemented in most machines, such as the online 905 906 Section 24 / Intermittent Renal Replacement Therapies monitoring of the ionic dialysance (to monitor the delivered dialysis dose) or blood volume. Dialysis Membrane Unmodified cellulosic membranes have a low molecular permeability and a low ultrafiltration coefficient compared with modified cellulosic or synthetic membranes (polysulfone, polymethylmethacrylate, polyacrylonitrile, polyamide). In addition, they are well known to activate the inflammation (complement and leukocytes activation) that is described as "bioincompatibility" properties. Randomized studies of the survival of acute renal failure patients in intensive care according to the type of membrane used11,12 do not yield a definitive conclusion because of the small total number of patients studied and conflicting results. However, meta-analyses suggest excess mortality with Cuprophan membranes, at the limit of significance. No study has reported any significant difference for major outcome between modified cellulosic or synthetic membranes as well as between different synthetic membranes. High-flux membrane and high surface may provide retrofiltration, increasing the risk of infectious complication. Pure Water the microbiologic quality of the prepared water is essential to achieve the best tolerance, including the absence of endotoxin, which may pass through the membrane from the dialysate to the vascular side. Inorganic and organic substances are removed from the water supply to obtain pure water. The water treatment system is composed with filters, a charcoal cartridge, and a reverse osmosis system. The water delivery may occur in three different ways: a central distribution from a specific water treatment system such as in chronic hemodialysis unit, a mobile water treatment incorporated in the dialysis machine, or more recently a batch-delivered system. Bicarbonate-based buffer is the standard buffer, given the hemodynamic effects provided by the old acetate-based buffer. For the electrolytic solution, particular attention must be paid to the potassium concentration (from 2 to 3 mmol/L) and the calcium concentration (from 1. Their final dialysate concentrations depend on the product used and are provided by the manufacturer. The final sodium concentration (from 140 to 150 mmol/L) and bicarbonate concentration (from 30 to 36 mmol/L), however, can be selected on the dialysis machine and may be modified during treatment. The dialysate flow can be modified in almost all machines (from 300 to 750 mL/min). Several other options may be used,16 including low-molecular-weight heparin, regional citrate anticoagulation, heparinoids, hirudin, or prostacyclin. Regional heparinization with protamine infusion is no longer recommended given the systemic anticoagulation usually observed. Regional citrate anticoagulation also may be used when heparin is contraindicated or for patients at high risk of bleeding. The latter requires a dialysis machine able to deliver dialysis using the mode "single needle" but is associated with higher recirculation, decreasing the delivered dialysis dose. The best insertion site providing the higher blood flow is the right jugular vein, but femoral access still remains the emergency site and is associated with the lower rate of acute complication during insertion. Concerning the rate of nosocomial infection or catheter dysfunction between jugular and femoral access, recent data seem to challenge the usually reported higher rate of infection or catheter dysfunction with femoral access. Use of the long-term cuffed catheter may be considered after the acute phase in a stable patient, but the occurrence of systemic infection usually leads to catheter removal. The diameter of the catheter is important to consider to obtain a good blood flow with acceptable pressures. Given the high extravascular volume of urea distribution, we observe a significant increase of serum urea after each session that is called urea rebound. These variations involve the vascular compartment and may induce Chapter 149 / Intermittent Techniques for Acute Dialysis hemodynamic instability as well as cellular edema particularly deleterious for the brain. In this population, the main objectives are the metabolic control and the good hemodynamic tolerance to avoid any further damage to the kidney and other organs. When considered in a meta-analysis, these studies do not show that a higher dialysis dose was superior in terms of mortality or dependence on chronic dialysis. An increase of the dialysis dose is required in certain clinical circumstances, such as life-threatening hyperkalemia, severe metabolic acidosis, and tumor lysis syndrome. This complication is of multiple origins, hypovolemia (fluid removal during the priming and during treatment), sodium and water loss (osmolality variation), and vascular vasodilation. It has been reported that high dialysate sodium concentration may reduce sodium loss at the initiation and osmolality variation during treatment. Mild dialysate hypothermia also may contribute to the better tolerance by the preservation of vascular tone. Unsurprisingly, the alternateday group experienced more frequent hypotensive episodes (25 ± 5% vs. In addition, even in the daily group, the delivered dose was lower than standard dose used in chronic dialysis. They found no differences between the two groups regarding 60-day survival, renal recovery, duration of renal support, and rate of organ failure. No definitive comparison can be drawn between this study and the other because the control group (less-intensive treatment) received a treatment definitively more intensive than the control group from Schiffl et al. Conventional Intermittent Hemodialysis this modality is derived directly from the use in chronic dialysis units. Hemodynamic tolerance of intermittent hemodialysis in critically ill patients: Usefulness of practice guidelines. Intermittent hemodialysis performed three or four times per week is a common modality for treating patients with acute renal failure. A target delivered dose of dialysis must be determined, and specific settings must be used to provide the target dose. Evidence to support the use of specific dialysis membranes or higher doses of dialysis to improve patient outcomes remains limited. Sequential Intermittent Hemodialysis Ultrafiltration and diffusion are not performed simultaneously during the same session. Usually, ultrafiltration is performed alone to manage the fluid balance; thereafter diffusion is used alone. Continuous renal replacement therapy versus intermittent hemodialysis in intensive care patients: impact on mortality and renal recovery. Sustained Low-Efficiency Dialysis the principle of this method is to decrease the solute clearance and to maintain the treatment over prolonged periods of time. Different terminology has been proposed in the literature: prolonged intermittent renal replacement therapy, extended daily dialysis, and sustained low-efficiency dialysis. The principal characteristic of these therapies is the prolonged treatment time and the low efficiency to permit slow removal of fluids with better hemodynamic tolerance and enhanced molecule removal. Usually, the dialysate and the blood flow rate are decreased (respectively 100 mL/min and 200 mL/min), and the session duration is increased (8 to 12 hours). Therefore the refilling from the interstitium to the vascular bed is enhanced, and given Chapter 149 / Intermittent Techniques for Acute Dialysis 908. Acute renal failure in critically ill patients: a multinational multicenter study. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. Biocompatible membranes in acute renal failure: prospective case-controlled study. Haemodialysis-membrane biocompatibility and mortality of patients with dialysisdependent acute renal failure: a prospective randomised multicentre trial. Anticoagulation for renal replacement therapy for patients with acute kidney injury. Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta analysis. Hemodynamic tolerance of intermittent hemodialysis in critically ill patients: usefulness of practice guidelines.

500 mcg fluticasone order. What asthma is like.

Hennessy Three high-quality evidence-based clinical practice guidelines recently have been published asthma symptoms in 12 year old quality fluticasone 500 mcg,6­8 and the use of one of these guidelines is advised strongly in clinical practice asthma death order fluticasone on line amex. Several of the specific recommendations are consistent across all three guidelines (Box 80 asthma treatment live fish purchase fluticasone 250 mcg mastercard. Outline three alternative strategies for patients with enteral feeding intolerance asthma questions and answers purchase cheapest fluticasone. Discuss how to optimize the choice of substrates (particularly glutamine and omega-3 fatty acids) in the composition of enteral nutrition asthma bronchiale bei kindern fluticasone 100 mcg order online. Enteral nutrition should be supplemented with parenteral nutrition if nutritional goals are not met but only after attempts at a promotility drug and a small bowel feeding tube. Cisapride accelerates gastric emptying and lowers gastric residual volume45,46 but is unfortunately no longer commercially available because of the risk of cardiac dysrhythmia. Despite its useful gastric emptying effect, it had no effect on nosocomial pneumonia or mortality rate. Nevertheless, careful use of either erythromycin or metoclopramide seems warranted when the first signs of enteral feeding intolerance develop. Erythromycin is more likely to be effective, although if intolerance persists with the use of either drug, the combination of both seems reasonable practice. The most likely such reason is a condition in which the gut is expected to be dysfunctional for many days, although patients with esophageal surgery,20 intestinal perforation and peritonitis,21 colorectal surgery,22,23 abdominal aortic aneurysm surgery,24 and acute pancreatitis25,26 can be readily enterally fed with few complications. However, gastric motility (particularly gastric emptying) and absorption are impaired in critical illness,30­32 and this may lead to enteral feeding intolerance. Whether a promotility drug should be tried before a small bowel feeding tube is placed is not well established at the present time, but recent clinical practice surveys have suggested that clinicians prefer promotility drugs to small bowel feeding,60,61 seemingly because of the logistical and technical concerns that are associated with nasojejunal tube placement. Chapter 80 / Enteral Nutrition Numerous insertion techniques have been described,62 and although "blind" placement at the bedside is certainly the least logistically challenging, this is time consuming and less successful than the placement of a nasogastric tube. Institutional considerations should determine which insertion technique is chosen, and because gastric residual volumes often remain large (placing the patient at risk of pneumonia), a promotility drug, such as metoclopramide or erythromycin, is recommended, as is the use of a supplementary nasogastric tube to drain this gastric fluid. Begin with gastric feeding within 24 hours of admission 471 Is gastric residual volume > 200 mL Yes Commence erythromycin (250 mg qid) No Continue feeding as is Is gastric residual volume > 200 mL Yes Commence metoclopramide (10 ­ 20 mg qid) No Supplementary Parenteral Nutrition Parenteral nutrition often has been considered an easy option for enteral feeding intolerance (especially when it is severe), as most critically ill patients already have central venous access. Although two recent clinical practice guidelines7,8 recommend supplementary parenteral nutrition to assist meeting nutritional goals in the presence of enteral feeding intolerance, caution is advised, as supplementary parenteral nutrition has been shown to lead to excess mortality in burn patients68 and has not been shown to improve clinical outcomes over enteral nutrition alone in meta-analyses. All three recently published evidence-based guidelines have suggested that a standard polymeric enteral formula should be administered,6­8 and this seems reasonable for most critically ill patients. Estimation of energy and protein requirements should be performed using standardized equations leading to an hourly goal rate being established. In some specific patient groups, evidence is accumulating that varying the nutrient composition with the aims of either replacing important deficiencies or modulating immune function may be useful, although controversy in this area continues. Clinicians should consider carefully the composition of the enteral nutrition with regard to lipid content, antioxidants, and glutamine as clinical outcomes are improved in some specific groups of patients. The way of the future must be to study the individual nutrients in specific disease states rather than the immunonutrition package in heterogeneous populations. Nutritional support leads to a reduction in complication rates and shorter hospitalization in critically ill patients, especially when evidencebased guidelines are followed. Enteral nutrition should be preferred to parenteral because of improved gut function, reduced infectious complications, and less expense. It should be started within 24 to 48 hours of intensive care unit admission in any patient with a functioning gut. Patients can be intolerant of gastric feeding as a result of impaired upper gut motility; this should be recognized and treated as it may lead to pneumonia. However, the balance appears to be in favor of early enteral nutrition rather than avoiding intolerance by delaying feeding. Erythromycin and metoclopramide should be used when intolerance occurs; however, a nasojejunal tube should be inserted when the intolerance does not resolve quickly and in preference to supplementary parenteral nutrition. It always should be added to any supplemental parenteral nutrition used in patients in the intensive care unit. Omega-3 fatty acids should be part of the enteral nutrition composition in patients with acute lung injury and sepsis because of their important antiinflammatory effects. In patients with renal failure, there should be careful attention to the amount of energy, protein, vitamins, and trace elements administered depending on the patient and the type of continuous renal replacement therapy being used. Omega-3 Fatty Acids There have now been two recent studies79,80 in which enteral nutrition products containing fish oil (eicosapentaenoic acid), borage oil (gamma-linolenic acid), and antioxidants led to beneficial clinical outcomes in patients with acute lung injury and septic shock. Although some clinicians feel that restriction of fluid and protein may be required when renal failure is present, there is little evidence to support this notion and there seems a greater rationale to use either earlier or more effective continuous renal replacement therapy to improve outcomes. What is known is that amino acids (including glutamine), vitamins, and trace elements often are lost from the body through the filter in continuous renal replacement therapy, although the exact amount in individual patients varies. The threshold to use promotility drugs, small bowel feeding tubes, and supplemental parenteral nutrition therefore should be lowered to maximize nutritional intake. Effects of enteral and parenteral nutrition on gut mucosal permeability in the critically ill. When intolerance occurs, small bowel feeding and promotility Chapter 80 / Enteral Nutrition 472. In1995acorrelation between malnutrition and poor outcome in critically ill patients still exists. Effectsofimmediate postoperative enteral nutrition on body composition, muscle function, and wound healing. Enteral versus parenteral feeding: effects on septic morbidity after blunt and penetrating abdominal trauma. Evidence-based guidelines for nutritional support of the critically ill: Results of a bi-national guideline development conference; 2005. Early postoperative enteral nutrition improves gut oxygenation and reduces costs compared with total parenteral nutrition. Modulating effects of the feeding route on stress response and endotoxin translocation in severely stressed patients receiving thoracic esophagectomy. Effect of low-calorie parenteral nutrition on the incidence and severity of hyperglycemia in surgical patients: A randomized, controlled trial. Randomized clinical trial comparing feeding jejunostomy with nasoduodenal tube placement in patients undergoing oesophagectomy. Early postoperative enteral feeding in patients with nontraumatic intestinal perforation and peritonitis. Early enteral nutrition within 24 h of colorectal surgery versus later commencement of feeding for postoperative complications. Comparison of tolerance and change of intragastric pH between early nasogastric and nasojejunal feeding following resection of colorectal cancer. Distal small bowel motility and lipid absorption in patients following abdominal aortic aneurysm repair surgery. A randomized controlled trial of enteral versus parenteral feeding in patients with predicted severe acute pancreatitis shows a significant reduction in mortality and in infected pancreatic complications with total enteral nutrition. Planas M, for the Nutritional and Metabolic Working Group of the Spanish Society of Intensive Care Medicine and Coronary Units. Gastroduodenal motility in mechanically ventilated critically ill patients: a manometric study. Delayed gastric emptying in ventilated critically ill patients: measurement by 13 C-octanoic acid breath test. Upper digestive intolerance during enteral nutrition in critically ill patients: Frequency, risk factors, and complications. Randomized comparison of nasojejunal and nasogastric feeding in critically ill patients. Enteral nutrition in the critically ill: a prospective survey in an Australian intensive care unit. Effectsofearlyenteral nutrition on intestinal permeability and the development of multiple organ failure after multiple injury. Effectoferythromycinon gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. Erythromycin improves gastric emptying in critically ill patients intolerant of nasogastric feeding. Erythromycin reduces delayed gastric emptying in critically ill trauma patients: a randomized, controlled trial. Erythromycin dose of 70 mg accelerates gastric emptying as effectively as 200 mg in the critically ill. Enteral naloxone reduces gastric tube reflux and frequency of pneumonia in critical care patients during opioid analgesia. Gastricemptying in critically ill patients is accelerated by adding cisapride to a standard enteral feeding protocol: Results of a prospective, randomized, controlled trial. A randomized trial of endoscopic and fluoroscopic placement of postpyloric feeding tubes in critically ill patients. The new frictional nasojejunal tube: A high success rate in achieving small bowel placement in critically ill patients; 2004. Proceedings of the 29th Australian and New Zealand Scientific Meeting on Intensive Care, p 53. Evaluation of three different strategies for post-pyloric placement of enteral feeding tubes. Glutamine supplementation in serious illness: a systematic review of the evidence. Glutamine dipeptide for parenteral nutrition in abdominal surgery: a meta-analysis of randomized controlled trials. L-alanyl-Lglutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: the French controlled, randomized, double-blind, multicenter study. Randomized trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma. Preclinical trial of L-arginine monotherapy alone or with N-acetylcysteine in septic shock. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Practical implications of nutritional support during continuous renal replacement therapy. Cisapride improves gastric emptying in mechanically ventilated, critically ill patients. Useofnovelprokineticagentsto facilitate return of gastrointestinal motility in adult critically ill patients. Erythromycin is more effective than metoclopramide in the treatment of feed intolerance in critical illness. Migrating motility complexes persist after severe traumatic shock in patients who tolerate enteral nutrition. Effect of postpyloric feeding on gastroesophageal regurgitation and pulmonary microaspiration: Results of a randomized controlled trial. Multicenter, prospective, randomized, single-blind study comparing the efficacy and gastrointestinal complications of early jejunal feeding with early gastric feeding in critically ill patients. Nutritional outcome and pneumonia in critical care patients randomized to gastric versus jejunal tube feedings. Gastricversussmall-boweltube feeding in the intensive care unit: a prospective comparison of efficacy. A comparison of early gastric and post-pyloric feeding in critically ill patients: a meta-analysis. Gastrointestinal promotility drugs in the critical care setting: a systematic review of the evidence. Bedside method for placing small bowel feeding tubes in critically ill patients: a prospective study. A posthoc analysis of this study published in 2009 identified that high nurse:patient ratio was associated independently with a lower risk of in-hospital death. Review risk factors and strategies to decrease microbial resistance including antimicrobial stewardship. Discuss particular characteristics pertinent to critically ill patients such as immunosuppression. Despite increased awareness, early recognition, and treatment with antibiotics, community-acquired and hospital-acquired infections continue to contribute substantially to the morbidity and mortality of critically ill patients. Common infection sites include pneumonia, bloodstream infections, intravascular catheter-related infections, intraabdominal infections, urosepsis, and surgical wound infections. Because of the numerous medications and interventions used only in the intensive care unit, critically ill patients often present unique obstacles that clinicians caring for them must overcome when diagnosing infection. Furthermore, because of factors such as old age, the use of immunosuppressive medications, and extracorporeal circuits, the absence of fever does exclude infection as a cause of deterioration of an unstable patient. There are two different species of Enterococcus known as frequent pathogens in humans: Enterococcus faecium and Enterococcus faecalis. Common infections resulting from this organism include urinary tract infections (most often catheter or instrumentation associated), meningitis in head trauma or postneurosurgery procedure, bacteremia resulting from catheter-related infection or hepatobiliary sepsis, and peritonitis. Unfortunately, the inappropriate use of broad-spectrum antibiotics has led to the appearance of very resistant organisms, including resistance to carbapenems. Resistance to echinocandins is uncommon; therefore when the decision to start an antifungal is made, an echinocandin should be considered as a first choice. Delay in starting adequate antimicrobials is associated with a high mortality; therefore it is recommended that initial antimicrobials should be broad spectrum with subsequent de-escalation. In comparison, septic shock is a subset of sepsis in which there is profound circulatory, cellular, and metabolic abnormalities. Antibiotic stewardship entails coordinated interventions to improve and measure the appropriate use of antimicrobials. Those strategies include education and development of clinical guidelines, preprescription approval, postprescription review and feedback,18 and computer-based interventions. These decisions should be made not based on protocol but based on medical judgment and complete review of clinical and laboratory data. When those factors are taken into account, it can be safe to use short courses of antimicrobials.

Current technologies still remain inadequate for the removal of middle-molecular-weight substances asthma treatment for pregnancy fluticasone 250 mcg order amex, and the current practice worldwide is extremely variable asthmatic bronchitis pneumonia purchase 500 mcg fluticasone amex. To address these limitations asthma like bronchitis generic fluticasone 500 mcg buy line, several approaches are worthy of further investigation asthma x ray center generic fluticasone 500 mcg. One of them would be to increase the porosity of membranes to improve middle molecular clearance asthma and allergy center fluticasone 250 mcg purchase free shipping. Such high-porosity hemofiltration has been tested in animals with promising results. Large multicenter trials evaluating the efficacy of these therapies to improve valid clinical outcomes. Multicenter randomized controlled trials are needed to test these promising blood purification technologies. Hemofiltration in human sepsis: Evidence for elimination of immunomodulatory substances. Modulation of chemokine gradients by apheresis redirects leukocyte trafficking to different compartments during sepsis, studies in a rat model. There is currently a clear biologic rationale for blood purification used in sepsis. Immunomodulation and organ support play important roles in the application of blood purification. Conventional continuous venovenous hemofiltration and hemodialysis have been shown not to be effective in sepsis in the absence of concomitant acute renal failure. Plasma therapies, high-volume hemofiltration, hemadsorption, or combinations of these therapies appear promising. The effect of intensive plasma water exchange by hemofiltration on hemo-dynamics and soluble mediators in canine endotoxemia. Infectious Diseases Society of America/AmericanThoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Preliminary report regarding the use of selective sorbents in complex cardiac surgery patients with extensive sepsis and prolonged intensive care stay. Clinical manifestations of disordered microcirculatory perfusion in severe sepsis. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria. Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients-United States, 2005. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. The effect of selective cytopheretic device on acute kidney injury outcomes in intensive care unit: a multicenter pilot study. Cawcutt and Andrea Zimmer to portend significant morbidity and mortality among transplant recipients. Recognize risk for and manifestations of common opportunistic infections in renal transplant recipients admitted to the intensive care unit. Describe appropriate evaluation and treatment for infections in renal transplant recipients admitted to the intensive care unit. Postoperatively, intensive immunosuppressive therapy is used to prevent acute rejection and preserve renal graft function. The level and duration of immunosuppression correlates with increased risk of developing opportunistic infections. Unfortunately, current donor pools (live or cadaveric) cannot meet the increasing need of potential recipents. Infection in immunocompromised hosts carries a broad spectrum of potential pathogens and atypical presentations of infection compared with the general population. A thorough medical history including travel, prior infections, environmental exposures, and immunization history should be obtained. Because risk of acute cellular rejection is highest in the first several months after transplantation, patients are given induction immunosuppression perioperatively and subsequently placed on long-term maintenance immunosuppression. Infections occur in a generally predictable pattern after solid-organ transplantation. Subsequently, an ongoing assessment of the risk of infection is used to adjust prophylaxis and immunosuppressive therapy. Depending on donor and recipient serostatus and duration of antiviral prophylaxis, delayed infections resulting from herpesviruses also can occur, primarily because of reactivation of latent infection in recipient or primary infection transmitted via the allograft. If the course is complicated by rejection, patients often require augmented immunosuppression. Prolonged and intensive immunosuppression increases risk for opportunistic infections and in an effort to reduce risk of the most common infections, antimicrobial prophylaxis often is used. The most common infections after kidney transplant are urinary tract infections and can occur shortly after the procedure. Other nosocomial infections, including pneumonia, central venous catheter­related infections, and Clostridium difficile infection can be seen during this time. Recurrent infections may indicate anatomic complications or retained nidus of infection. Pseudomonas aeruginosa and other nosocomial pathogens such as Enterococcus species are also common. Most centers use trimethoprimsulfamethoxazole for prophylaxis against Pneumocystis jiroveci, which also offers protection against infections resulting from Listeria spp. However, if this is not prescribed or taken, all of the aforementioned infections can be seen. Reactivation of tuberculosis or endemic/dimorphic fungi (Histoplasma capsulatum, Coccidioides immitis, and Blastomyces dermatitidis) also should be considered in patients with the appropriate clinical scenario and exposure. Clinical manifestations of pneumonia may be subtler initially and require clinicians to maintain a high level of suspicion. Blood cultures should be drawn in the setting of sepsis to ascertain concomitant bloodstream infection and possible metastatic sites of infection, because this may alter antimicrobial choices and duration of therapy. Empiric antimicrobial therapy should be based on exposure risks, antibiograms, and individual patient issues (allergies, drug interactions, comorbidities) and tailored appropriately on susceptibilities. Assessment of source control with imaging to rule out abscess in more superficial infections may be of value also in this setting. Active infection with tuberculosis does portend an increased morbidity and mortality to transplant patients. However, in the setting of the immunosuppression, patients may have extrapulmonary symptoms/sites of infection. Consideration of active infection should prompt respiratory isolation in a negatively pressured, externally vented single room to avoid patient-to-patient spread. Tuberculin skin tests and interferon gamma release assays are intended for assessment of latent tuberculosis, not active infection; therefore culture, nucleic acid testing, or tissue specimen with staining for acid-fast bacilli should be obtained for a confirmed diagnosis and drug susceptibility testing. Specific testing, including acid-fast staining and mycobacterial culture media, should be requested if these organisms are being considered in the differential diagnosis. Antimicrobial therapy is usually a prolonged course (6 to 12 months) based on antimicrobial susceptibility. Antimicrobial use is common given the risk of posttransplant infections and is the primary modifiable risk factor. Further, recent surgical procedures and immunosuppression also increased the overall risk. Viral Infections Viral infections in renal transplant patients have a wide range of presentations with potential short-term and longterm sequelae, such as susceptibility to other infections, allograft dysfunction, rejection, and malignancy. Both agents require dose adjustments in the setting of renal dysfunction, and valganciclovir should not be used in patients requiring hemodialysis. Both agents can cause myelosuppression heralded by leukopenia and/or thrombocytopenia. The viral load may continue to rise for the first 7 to 10 days after starting antiviral treatment, but occasionally the virus can develop resistance. In patients with rising viral loads despite more than 14 days of treatment with appropriately dosed ganciclovir or valganciclovir, testing for antiviral resistance and initiation of alternative therapy may be indicated. Suggested tests for each viral pathogen are discussed in their individual sections. These viruses establish latency after initial infection and can reactivate during periods of immunosuppression. One option is to provide antiviral prophylaxis (intravenous ganciclovir or oral valganciclovir) to at-risk individuals during high-risk periods. The use of antiviral agents such as acyclovir or ganciclovir and/ or immunoglobulin is controversial but may be considered as an adjunctive therapy. The virus then establishes latency in the urinary tract and can have asymptomatic viral shedding in the normal population. Because rejection also is included in this differential and requires very different management, renal biopsy usually is undertaken to differentiate between the two and to stage the severity. The use of immunoglobulin and antiviral agents is controversial because there are no definitive data that they provide any benefit, and some have associated toxicities. Obtaining cells or tissue for cyto- or histopathology with intranuclear inclusions and immunochemistry helps to confirm diagnosis but is not always feasible. In the absence of disseminated disease, oral antiviral treatment with acyclovir, valacyclovir, or famciclovir is likely adequate. Some serotypes are capable of establishing latent infections and can reactivate or be transmitted via allograft. Adenovirus can cause a wide variety of illnesses, including upper and lower respiratory tract infections, conjunctivitis, enteritis, and hepatitis. However, the case-fatality rate is the highest for fungal infections compared with other pathogen categories, and therefore, if infections occur, prompt recognition and treatment is important. Most fungal infections occur within the first 6 months after transplantation, although a longer period of risk may occur in more heavily immunosuppressed recipients. These viruses are transmitted by direct contact and respiratory droplets from infected individuals and typically follow a seasonal pattern. The clinical presentation made include upper respiratory tract infection, tracheobronchitis, influenza-like illness, bronchiolitis, or pneumonia. Influenza is typically the most severe of the aforementioned viral infections, and treatment with a neuraminidase inhibitor such as oseltamivir or zanamivir usually is indicated, because it may shorten the duration of symptoms and prevent progression to more severe illness. Newer agents, such as intravenous peramivir, are not used routinely in critically ill or immunocompromised patients. Treatment recommendations should be reviewed yearly for updates in recommendations and management. The treatment for the rest of the aforementioned viral infections is usually supportive in the renal transplant population. Older age, central venous catheters, surgical drains, urinary catheters, diabetes mellitus, use of corticosteroids or broad-spectrum antibiotics, and length of hospital and intensive care unit stay are important risk factors for the development of Candida infection in transplant recipients. Oral candidiasis manifests as single or multiple, white, raised, plaque-like lesions over the palate and oropharyngeal mucous membranes and often can be treated with topical agents. Oral candidiasis can progress distally and can lead to esophageal involvement with symptoms ranging from asymptomatic to odynophagia/dysphagia. Esophageal candidiasis, if untreated, can lead to esophageal bleeding, perforation, and disseminated candidiasis. Candiduria may represent asymptomatic colonization in renal recipients with indwelling bladder catheters versus lower or upper tract infection. Deep-seated candidiasis can manifest with persistent fever or sepsis in patients who are receiving antibacterial therapy or have other risk factors for candidiasis. Definitive diagnosis of invasive candidiasis is based on isolation of the organism from sterile source. Therefore isolation of Candida from one or more blood cultures always should be considered to represent a true pathogen. Candidemia may be the result of deep tissue-invasive candidiasis or catheter-related infection, in which case, line removal is recommended strongly. Other signs of dissemination include skin lesions or new ocular symptoms, including eye pain, photophobia, and visual loss, which may signify Candida endophthalmitis and should prompt an ophthalmology evaluation with dilated eye exam. Treatment for deep-seated Candida infections or candidemia requires a systemic antifungal agent and options include azoles, echinocandins, and liposomal amphotericin B. Once the species has been identified, treatment can be guided by likely susceptibility prolife. Hepatitis C is of particular concern because it further blunts the immune system if not treated before transplant. For those who receive infected donor organs, development of active infection is variable in presentation but can be very rapid in clinical progression. Further, in the setting of immunosuppression, antibodies may not form for seroconversion, thus nucleic acid testing should be used to assess for infection. Although the main portal of entry is the respiratory tract, Cryptococcus pneumonia is seen relatively infrequently. More concerning, this infection can disseminate hematogenously and spread to the central nervous system and lead to subacute meningitis. Diagnosis requires the detection of Cryptococcus in the cerebrospinal fluid by India ink staining, identification of cryptococcal antigen, or culture. They are termed dimorphic because they grow as yeast at warmer temperature (body) and as mycelial forms at cooler temperature (lab) and therefore appear as yeast on histopathology but grow as molds in culture. For severe disease, liposomal amphotericin is the preferred initial drug with eventual transition to an azole pending organ involvement and clinical course. These infections can reactivate from latent infections, be donor derived, or occur de novo posttransplantation. In addition, corticosteroids should be considered for those with significant hypoxia (partial pressure of oxygen in the alveoli of <70 mm Hg on room air). Any of these may experience headache, fever, nuchal rigidity, impaired consciousness, or change in cognitive function.

References

• Akhtar S, Meeran SM, Katiyar N, Katiyar SK. Grape seed proanthocyanidins inhibit the growth of human non-small cell lung cancer xenografts by targeting insulin-like growth factor binding protein-3, tumor cell proliferation, and angiogenic factors. Clin Cancer Res 2009;15(3):821-31.
• Diamant M, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-2243.
• Peat G, Thomas E. When knee pain becomes severe: a nested casecontrol analysis in community- dwelling older adults. J Pain 2009; 10:798-808.
• Ali-Hassan-Sayegh S, Mirhosseini SJ, Tahernejad M, et al. Impact of antioxidant supplementations on cardio-renal protection in cardiac surgery: an updated and comprehensive meta-analysis and systematic review. Cardiovasc Ther 2016;doi:10.